KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) EBT (2016 - 2025)

Fulgent Genetics (FLGT) has disclosed EBT for 11 consecutive years, with $32.5 million as the latest value for Q4 2025.

  • Quarterly EBT rose 1219.4% to $32.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$8.3 million through Dec 2025, up 82.35% year-over-year, with the annual reading at -$8.3 million for FY2025, 82.34% up from the prior year.
  • EBT hit $32.5 million in Q4 2025 for Fulgent Genetics, up from -$7.5 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $267.2 million in Q1 2021 to a low of -$145.2 million in Q4 2023.
  • Historically, EBT has averaged $31.6 million across 5 years, with a median of -$5.2 million in 2024.
  • Biggest five-year swings in EBT: skyrocketed 16071.55% in 2021 and later plummeted 370.15% in 2024.
  • Year by year, EBT stood at $150.8 million in 2021, then tumbled by 122.19% to -$33.5 million in 2022, then crashed by 333.91% to -$145.2 million in 2023, then skyrocketed by 98.0% to -$2.9 million in 2024, then soared by 1219.4% to $32.5 million in 2025.
  • Business Quant data shows EBT for FLGT at $32.5 million in Q4 2025, -$7.5 million in Q3 2025, and -$21.5 million in Q2 2025.